Full Title Sex Differences in Management, Time to Intervention, and In-Hospital Mortality of Acute Myocardial Infarction and Non-Myocardial Infarction Related Cardiogenic Shock **Authors** Anushka Desai, BS¹; Rohan Rani, BS¹; Anum Minhas, MD MHS²; Faisal Rahman BM BCh² 1. Georgetown University School of Medicine 2. Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. **Short Title** Sex Differences in Cardiogenic Shock **Corresponding Author Information** Anushka Desai ad1551@georgetown.edu 3603 T Street NW Washington D.C., 20007 **Total Word Count – 2,218** Acknowledgements None **Sources of Funding** Dr. Minhas is supported by NIH/NHLBI K23HL171886. **Disclosures** None

Abstract

42 <u>Background</u>

41

45

52 53

65 66

- 43 Limited data are available on sex differences in the time to treatment of cardiogenic shock (CS)
- with and without acute myocardial infarction (AMI).
- 46 Methods
- 47 For this retrospective cohort study, we used nationally representative hospital survey data from
- 48 the National Inpatient Sample (years 2016-2021) to assess sex differences in interventions, time
- 49 to treatment (within versus after 24 hours of admission), and in-hospital mortality for AMI-CS
- and non-AMI-CS, adjusting for age, race, income, insurance, comorbidities, and prior cardiac
- 51 interventions.
 - Results
- We identified 1,052,360 weighted CS hospitalizations (60% non-AMI-CS; 40% AMI-CS).
- Women with CS had significantly lower rates of all interventions. For AMI-CS, women had a
- higher likelihood of in-hospital mortality after: revascularization (adjusted odds ratio (aOR) 1.15
- 57 [95% CI 1.09-1.22]), mechanical circulatory support (MCS) (1.15 [1.08-1.22]), right heart
- catheterization (RHC) (1.10 [1.02-1.19]) (all p<0.001). Similar trends were found for the non-
- 59 AMI-CS group. Women with AMI-CS were less likely to receive early (within 24 hours of
- admission) revascularization (0.93 [0.89-0.96]), MCS (0.76 [0.73-0.80]), or RHC (0.89 [0.84-
- 61 0.95]) than men; women with non-AMI-CS were less likely to receive early revascularization
- 62 (0.78 [0.73-0.84]), IABP (0.85 [0.78-0.94]), pLVAD (0.88 [0.77-0.99]) or RHC (0.83 [0.79-
- 63 0.88]) than men (all p<0.001). For both types of CS, in-hospital mortality was not significantly
- different between men and women receiving early ECMO, pLVAD, or PCI.
 - Conclusions
- Sex disparities in the frequency of treatment of CS persist on a national scale, with women being
- 68 more likely to die following treatment and less likely to receive early treatment. However, when
- 69 comparing patients who received early treatment, in-hospital mortality does not differ
- significantly when men and women are treated equally within 24 hours of admission. Early
- 71 intervention if clinically indicated could mitigate sex-based differences in CS outcomes and
- should be made a priority in the management of CS.

Clinical Perspective

What is new?

81

83

84

85

86

87 88 89

90

91

92 93

94 95 96

- Women have increased in-hospital mortality with cardiogenic shock and have lower odds of early intervention (within 24 hours of admission) compared to men.
- When men and women with cardiogenic shock are treated equally in terms of early intervention within 24 hours of admission, sex differences in in-hospital mortality disappear.

What are the clinical implications?

- Sex-based disparities are present in the utilization of treatment and time to intervention for patients with cardiogenic shock.
- Early recognition and intervention for cardiogenic shock among women should be considered to improve clinical outcomes.

Abbreviations

- 97 CS Cardiogenic Shock
- 98 AKI Acute Kidney Injury
- 99 AMI Acute Myocardial Infarction
- 100 MCS Mechanical Circulatory Support
- 101 RHC Right Heart Catheterization
- 102 HCUP Healthcare Cost and Utilization Project
- 103 NIS National Inpatient Sample
- 104 PCI Percutaneous Intervention
- 105 CABG Coronary Artery Bypass Graft
- 106 IABP Intra-Aortic Balloon Pump
- 107 pLVAD Percutaneous Left Ventricular Assist Device
- 108 LVAD Left Ventricular Assist Device
- 109 ECMO Extracorporeal Membrane Oxygenation
- 110 aOR Adjusted Odds Ratio

Introduction

Cardiogenic shock (CS) is defined as a state of decreased circulation causing hypoxia and endorgan hypoperfusion. It is frequently precipitated by acute myocardial infarction (AMI). Despite advancements in medical interventions over the past 20 years, CS remains associated with high mortality ranging between 30-50%. There exist marked sex disparities in mortality associated with CS in the United States. Current literature suggests insufficient recognition of symptoms in women, faltering guideline-directed medical therapy during the first 24 hours, and inadequate utilization of mechanical circulatory support (MCS) devices as underlying reasons for the observed mortality difference.

In all patients, rapid deterioration following CS necessitates timely intervention to improve clinical outcomes. ^{10,11} Recently, the DanGer Shock trial has driven the point of early aggressive treatment of AMI-CS, finding that prompt routine use of percutaneous left ventricular assist devices (pLVAD) decreases the risk of all-cause mortality. ¹² This is especially pertinent when considering a recent cohort study that found women to be less likely to receive pLVAD when hospitalized for CS. ¹³ Given that earlier intervention can result in improved clinical outcomes, we aimed to investigate whether differences in timely intervention were associated with higher mortality among women compared to men.

Methods

162 Study Data

161

169

176

184

192

- Data was obtained from the Healthcare Cost and Utilization Project (HCUP) National Inpatient
- Sample (NIS) database, which is sponsored by the Agency of Healthcare Research and Quality.
- The NIS is the largest publicly available all-payer administrative database in the United States. It
- 166 contains hospitalization data from a stratified 20% sample of over 1,000 hospitals across the
- nation participating in the HCUP, and, when weighted, can be used to estimate nationwide trends
- and incidence.
- 170 <u>Study Population & Outcomes</u>
- 171 The database was queried for adult patients (≥18 years) admitted with CS from 2016 to 2021,
- using the International Classification of Disease 10th Revision Clinical Modification Codes of
- 173 R57.0. We categorized these hospitalizations by the presence of AMI on admission into two
- 174 cohorts: non-AMI CS and AMI-CS. Hospitalizations missing mortality or sex data were
- excluded. Study flowchart is included in **Figure S1**.
- 177 Baseline demographics, comorbidities, and prior interventions were identified with ICD-10-CM
- 178 codes. These characteristics included census-defined age group, race/ethnicity, quartile of
- median household income, insurance, hospital type, hospital teaching status, obesity,
- dyslipidemia, diabetes mellitus, hypertension, tobacco use, peripheral vascular disease, chronic
- heart failure, chronic kidney disease, chronic liver disease, valvular heart disease, coronary artery
- disease, stroke, prior percutaneous intervention (PCI), and prior coronary artery bypass graft
- 183 (CABG).
- The procedural outcomes analyzed were revascularization (Percutaneous Coronary Intervention
- 186 [PCI] and Coronary Artery Bypass Graft [CABG]), MCS (Intra-aortic Balloon Pump [IABP],
- Percutaneous Left Ventricular Assist Device [pLVAD], Extracorporeal Membrane Oxygenation
- 188 [ECMO]), RHC, and advanced heart failure therapies (LVAD and heart transplant). The clinical
- outcomes studied included in-hospital mortality, use of invasive mechanical ventilation, major
- bleeding, acute kidney injury, and stroke. **Table S1** includes a complete list of all ICD-10
- diagnosis and procedure codes used.
- 193 Statistical Analysis
- All data represent weighted national estimates, which were done using HOSP NIS as a
- 195 clustering variable and NIS STRATUM to account for different strata, as recommended by the
- 196 AHRQ methods. 14 Differences in baseline data, procedural outcomes, and clinical outcomes
- between the type of CS and sex were compared using Pearson's χ^2 test for categorical variables
- and the Mann-Whitney test for continuous variables.

Multivariable logistic regressions that accounted for survey weighting were used to assess sex differences in use of intervention at any point during hospitalization, early treatment (within 24 hours of admission), and adverse clinical outcomes for both AMI and non-AMI CS, adjusting for all baseline demographics, comorbidities, and prior interventions. Further subgroup analyses were performed to assess sex differences in in-hospital mortality associated with receiving early versus late intervention.

Statistical significance was defined with a type I error of < 0.05. All analyses were performed using STATA Statistical Software version 18.0.

Results

240

248249

257258

270271

- 241 Baseline Characteristics
- Our study included 1,052,360 weighted hospitalizations with CS between 2016 and 2021. As
- seen in **Table 1**, both non-AMI-CS and AMI-CS had a higher incidence in men compared to
- 244 women (non-AMI-CS 61.8% vs 38.1%; AMI-CS 63.6% vs 36.3%; p<0.001). Women were more
- 245 likely to be older with CS. Women with CS, compared to men, had higher frequencies of obesity,
- valvular heart disease, and stroke, and lower frequencies of coronary artery disease and prior PCI
- 247 or CABG (p<0.001).

Procedural and Clinical Outcomes

- 250 For both types of CS, women had significantly lower frequencies of almost every type of
- intervention compared to men (p<0.001), the only exception being heart transplant for AMI-CS
- 252 (Table 2). Women had higher frequencies of in-hospital mortality, use of mechanical ventilation,
- and stroke during hospitalization, and lower frequencies of major bleeding events and acute
- 254 kidney injury compared to men. Hospital length of stay and total charges were significantly
- lower for women than men. These trends were observed after adjusting for baseline
- characteristics and comorbidities as well (**Tables S2-3**).

Outcomes after Intervention for AMI-CS

- Women with AMI-CS undergoing revascularization had higher mortality (aOR: 1.15; 95% CI:
- 260 1.09-1.22; p<0.001), were more likely to require mechanical ventilation (aOR: 1.07; 95% CI:
- 261 1.02-1.12; p=0.003), and have a stroke (aOR: 1.62; 95% CI: 1.12-2.35; p<0.001) during their
- 262 hospitalization compared to men (Table 3). When MCS was utilized, women were more likely to
- 263 have higher mortality (adjusted odds ratio (aOR): 1.15; 95% CI: 1.08-1.22; p<0.001), be placed
- on mechanical ventilation (aOR: 1.12; 95% CI: 1.06-1.19; p<0.001), or have a major bleeding
- event (aOR: 1.08; 95% CI: 1.01-1.15; p=0.01) during their hospitalization than men. After RHC,
- 266 women were more likely to die (aOR: 1.10; 95% CI: 1.02-1.19; p<0.001) or be placed on
- mechanical ventilation (aOR: 1.12; 95% CI: 1.04-1.21; p=0.002) during their hospitalization than
- 268 men. No significant differences in adverse clinical outcomes between men and women receiving
- advanced heart failure therapy were noted.

Outcomes after Intervention for non-AMI-CS

- Following revascularization, women with non-AMI-CS were more likely to die (aOR: 1.38; 95%)
- 273 CI: 1.23-1.56; p<0.001) and be placed on mechanical ventilation (aOR: 1.11; 95% CI: 1.00-1.24;
- p=0.050) during their hospitalization than men (**Table 4**). Women receiving MCS were more
- 275 likely to die (aOR: 1.31; 95% CI: 1.21-1.43; p<0.001), be placed on mechanical ventilation
- 276 (aOR: 1.28; 95% CI: 1.18-1.40; p<0.001), or have a major bleeding event (aOR: 1.10; 95% CI:
- 277 1.02-1.18; p=0.012) during their hospitalization than men. The same was true after RHC for in-
- 278 hospital mortality (aOR: 1.32; 95% CI: 1.22-1.43; p<0.001) and mechanical ventilation usage

(aOR: 1.27: 95% CI: 1.17-1.36: p<0.001). No significant differences in adverse clinical outcomes between men and women receiving advanced heart failure therapy were noted. Incidence and Mortality Following Early Intervention For both types of shock, women had a lower frequency of receiving CABG, IABP, pLVAD, and RHC within 24 hours of admission compared to men (Figure 1). Women with AMI-CS additionally had lower frequencies of undergoing placement on ECMO and PCI within 24 hours. This was similarly reflected after adjusting for covariates, with women with AMI-CS being less likely to receive any type of revascularization, MCS, or RHC than men, and women with non-AMI-CS being less likely to receive any type of revascularization, IABP, pLVAD, RHC, or LVAD than men (Figure 2). In-hospital mortality did not change significantly between men and women with AMI-CS undergoing early revascularization, pLVAD, ECMO, or RHC (Figure 3). For those with non-AMI-CS, in-hospital mortality did not change significantly when treated early with PCI, pLVAD, ECMO, or RHC (Figure 3). For AMI-CS, women receiving early interventions of any revascularization or within 24 hours were far less likely to die during their hospitalization than women who received intervention after 24 hours or not at all; meanwhile, for non-AMI-CS, this was the case for women receiving early CABG, IABP, or RHC (**Table 5**).

Discussion

To our knowledge, this study is the first to examine sex differences in management and outcomes of patients with AMI-CS and non-AMI-CS utilizing time to intervention. We found that (1) women with either type of CS are less likely to undergo interventions during hospitalization than men; (2) even after receiving intervention, in-hospital mortality, mechanical ventilation, and major bleeding are more likely to occur in women with CS than men; (3) among patients undergoing intervention, women are less likely to have an intervention performed within 24 hours of admission; (4) and with early intervention, there was no difference in mortality among women and men.

Previous studies have demonstrated that women are less likely to receive MCS therapies in CS and experience a 10% higher mortality risk. 11 Not only did we confirm these findings, but we also found that women had significantly lower frequencies of nearly all types of interventions compared to men and were less likely to receive these interventions early. This was associated with higher frequencies of in-hospital mortality, invasive mechanical ventilation, and stroke during hospitalization. Prior analyses of NIS data from 2006 to 2015 found that, for AMI-CS, women were more likely to die during their hospitalization than men (aOR 1.11, 95% CI: 1.06-1.16 p < 0.001). 15 Despite significant recognition of sex disparities in management and mortality rates of many conditions, our analysis shows that the situation has yet to improve significantly in the subsequent decade for CS.

The results of this study suggest that ongoing sex disparities in mortality and outcomes of CS may be related to time to intervention. When women and men are similarly treated with early intervention for CS, outcomes are comparable. Additionally, women with CS undergoing any revascularization, IABP, or RHC within 24 hours of admission were far less likely to die during their hospitalization than women who received intervention after 24 hours or not at all. Both of these findings point to late intervention as a plausible explanation for the observed outcome differences and demonstrate the tangible impact of timely intervention in narrowing the sex gap in clinical outcomes for CS.

Research has extensively explored the elevated mortality in women with CS, especially within the context of AMI. One hypothesis posits that women in low-output states are less likely to be recognized by providers as experiencing CS. This is supported by studies on sex-based differences in time to treatment for AMI, showing delays at every stage of care (from symptom onset to EMS call, EMS to hospital admission, and hospital admission to reperfusion therapy). ¹⁶ Early intervention has been shown to be crucial in the treatment of CS, lending to better post-procedure outcomes and lower rates of in- and out-hospital mortality. ^{17,18} Reasons for this include improved perfusion resulting in the prevention of irreversible ischemic damage and pathologic cardiac remodeling.

Clinically, improving recognition of low-output states in women can lead to decreased time to treatment for CS. When looking at the temporal trends of women undergoing AMI, female sex has been associated with a greater time to reperfusion even when adjusting for all baseline characteristics and types of reperfusion therapy used. ^{19,20} It is equally important to note that when performing a clinical assessment of suspected AMI, symptom presentation varies not only by sex, but also by race; for example, Black women are more likely to present with GI distress, while White women are more likely to present with typical chest pain. ²¹ Noting these differences in symptom presentation is significant, as an atypical presentation with acute-onset GI distress can modify the differential to include a diagnosis of GERD or peptic ulcer disease, which would subsequently contribute to poorer outcomes, especially in Black women.

Limitations

There were a few limitations that were present in this study. The diagnosis of CS was based on ICD-CM codes used for billing purposes, which are susceptible to erroneous coding. However, previous studies comparing ICD diagnosis of CS to physician adjudication in hospital systems that validate these codes have demonstrated that ICD-CM codes are reliably coded and can accurately predict mortality in the context of MI and CS. ^{22,23} Also, the NIS database recorded time in units of days as opposed to hours, so more exact timing information was not available. Data included information on hospitalizations as opposed to patient-level data, which opens the possibility of repeat patients in the sample. Additionally, specific data such as vital signs, laboratory, and echocardiogram data were not available. Finally, there was a lack of information on post-discharge outcomes, which could have provided further insight into post-intervention results from the management of CS.

Conclusions

Our study found that, despite stark differences in access to early intervention for CS between men and women, in-hospital mortality did not differ significantly between sexes when treated equally within 24 hours of admission. Early intervention plays a role in mitigating sex-based differences in CS outcomes and should be prioritized in the management of CS. Future research should focus on recognizing the atypical presentations of CS in women, identifying signs and symptoms earlier in the disease course, and validating our findings in other cohorts.

References

- 1. Daoulah A, Alshehri M, Panduranga P, et al. Clinical outcomes of patients with cardiogenic shock complicating acute myocardial infarction: The Gulf-Cardiogenic Shock (G-CS) Registry. Shock. 2024 Aug 12. doi:10.1097/SHK.0000000000002433. Epub ahead of print. PMID: 39158570.
- 2. Aissaoui N, Puymirat E, Delmas C, et al. Trends in cardiogenic shock complicating acute myocardial infarction. Eur J Heart Fail. 2020;22(4):664-672. doi:10.1002/ejhf.1750.
- 3. Bertaina M, Morici N, Frea S, et al. Differences between cardiogenic shock related to acute decompensated heart failure and acute myocardial infarction. ESC Heart Fail. 2023;10(6):3472-3482. doi:10.1002/ehf2.14510.
- 4. Chioncel O, Parissis J, Mebazaa A, et al. Epidemiology, pathophysiology and contemporary management of cardiogenic shock a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22(8):1315-1341. doi:10.1002/ejhf.1922.
- 5. Luna P, Kim LK, Yeo I, et al. Sex disparities in the management, outcomes, and transfer of patients hospitalized for cardiogenic shock. J Soc Cardiovasc Angiogr Interv. 2023;3(3Part A):101212. doi:10.1016/j.jscai.2023.101212. PMID: 39131782; PMCID: PMC11307867.
- 6. Takla A, Mostafa MR, Eid MM, et al. Sex difference in outcomes and management of cardiogenic shock: A systematic review and meta-analysis. Curr Probl Cardiol. 2024;49(11):102777. doi:10.1016/j.cpcardiol.2024.102777. Epub ahead of print. PMID: 39103132.
- 7. Abdallah N, Mohamoud A, Almasri T, et al. Relationships between sex and in-hospital outcomes of patients with acute cardiogenic shock receiving mechanical circulatory support. Cardiovasc Revasc Med. 2024 Jul 20:S1553-8389(24)00594-3. doi:10.1016/j.carrev.2024.07.017. Epub ahead of print. PMID: 39054172.
- 8. Elgendy IY, Wegermann ZK, Li S, et al. Sex differences in management and outcomes of acute myocardial infarction patients presenting with cardiogenic shock. JACC Cardiovasc Interv. 2022;15(6):642-652. doi:10.1016/j.jcin.2021.12.033. PMID: 35331456.
- 9. Suzuki S, Ito K, Teraoka N, et al. Treatment time limit for successful weaning from veno-arterial extracorporeal membrane oxygenation in cardiogenic shock. ESC Heart Fail. 2024 Jul 11. doi:10.1002/ehf2.14931. Epub ahead of print. PMID: 38992944.
- 10. Shirakabe A, Matsushita M, Shibata Y, et al. Organ dysfunction, injury, and failure in cardiogenic shock. J Intensive Care. 2023;11(1):26. doi:10.1186/s40560-023-00676-1. PMID: 37386552; PMCID: PMC10308671.
- 11. Fisher T, Hill N, Kalakoutas A, et al. Sex differences in treatments and outcomes of patients with cardiogenic shock: a systematic review and epidemiological meta-analysis. Crit Care. 2024;28(1):192. doi:10.1186/s13054-024-04973-5.
- 12. Møller JE, Engstrøm T, Jensen LO, et al. Microaxial flow pump or standard care in infarct-related cardiogenic shock. N Engl J Med. 2024;390(15):1382-1393.
- 13. Yan I, et al. Sex differences in patients with cardiogenic shock. ESC Heart Fail. 2021;8(3):1775-1783. doi:10.1002/ehf2.13303.
- 14. HCUP National Readmission Database (NRD). Healthcare Cost and Utilization Project
 (HCUP). Agency for Healthcare Research and Quality. Accessed October 09, 2021.
 https://www.hcup-us.ahrq.gov/nrdoverview.jsp
- 15. Ya'qoub L, Lemor A, Dabbagh M, et al. Racial, ethnic, and sex disparities in patients

with STEMI and cardiogenic shock. J Am Coll Cardiol Intv. 2021;14(6):653-660.
 doi:10.1016/j.jcin.2021.01.003.

- 16. Stehli J, Dinh D, Dagan M, et al. Sex differences in prehospital delays in patients with ST-segment–elevation myocardial infarction undergoing percutaneous coronary intervention. JAHA. 2021;10(13):e019938. doi:10.1161/JAHA.120.019938.
- 17. Azazy A, Farid WA, Ibrahim WA, El Shafey WEH. Survival benefit of IABP in preversus post-primary percutaneous coronary intervention in patients with cardiogenic shock. Egypt Heart J. 2024;76(1):99. doi:10.1186/s43044-024-00527-w. PMID: 39107654; PMCID: PMC11303647.
- 18. Brodie BR, Stuckey TD, Muncy DB, et al. Importance of time-to-reperfusion in patients with acute myocardial infarction with and without cardiogenic shock treated with primary percutaneous coronary intervention. Am Heart J. 2003;145(4):708-715. doi:10.1067/mhj.2003.9. PMID: 12679769.
- 19. Kaul P, et al. Temporal trends in patient and treatment delay among men and women presenting with ST-elevation myocardial infarction. Am Heart J. 2011;161(1):91-97. doi:10.1016/j.ahj.2010.09.016.
- 20. Lansky AJ, et al. Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2005;111(13):1611-1618. doi:10.1161/01.CIR.0000160362.55803.40.
- 21. Eastwood J, et al. Anginal symptoms, coronary artery disease, and adverse outcomes in Black and White women: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. J Womens Health. 2013;22(9):724-732. doi:10.1089/jwh.2012.4031.
- 22. Lambert L, et al. Evaluation of care and surveillance of cardiovascular disease: can we trust medico-administrative hospital data? Can J Cardiol. 2012;28(2):162-168. doi:10.1016/j.cjca.2011.10.005.
- 23. Lauridsen MD, Gammelager H, Schmidt M, et al. Positive predictive value of International Classification of Diseases, 10th revision, diagnosis codes for cardiogenic, hypovolemic, and septic shock in the Danish National Patient Registry. BMC Med Res Methodol. 2015;15:23. doi:10.1186/s12874-015-0013-2.

Table 1. Baseline characteristics of patients stratified by CS type and sex (weighted).

Non-AMI-CS 631,655 (60.0) 420,705 (40.0) Male Female 390,505 241,150 <0.001 267,810 152,895 <0.0 (61.8) (38.2) (63.7) (36.3)	01
Male 390,505 (61.8) Female 241,150 (63.7) P-value 267,810 (63.7) Female 267,810 (152,895) P-value 267,810 (63.7) P-value 267,810 (152,895) P-value 267,810 (15	01
390,505 241,150 <0.001 267,810 152,895 <0.001	01
(61.8) (38.2) (63.7) (36.3) Demographics Age Group 18-44 39,125 24,930 <0.001	
Demographics Age Group 18-44 39,125 24,930 <0.001	0.1
Age Group 18-44 39,125 24,930 <0.001	01
18-44 39,125 24,930 <0.001	01
(10.0) (10.3) (4.4) (3.8) 45-64 141,780 72,050 96,105 41,370	<u>በ1</u>
45-64 141,780 72,050 96,105 41,370	01
(36.3) (29.9) (35.9) (27.0)	
65-84 182,565 116,715 137,165 82,500	
(46.8) (47.4) (51.2) (53.9)	
85+ 27,035 27,455 22,695 23,230	
(6.9) (11.4) (8.5) (15.2)	
Race/Ethnicity	
White 246,835 147,395 <0.001 183,020 103,525 <0.0	01
(65.6) (63.4) (71.4) (70.4)	
Black 69,525 50,275 25,015 19,365	
(18.5) (21.6) (9.7) (13.2)	
Hispanic 34,005 19,785 25,700 13,000	
(9.0) (8.5) (10.0) (8.8)	
Asian 11,365 7,065 10,675 5,080	
$(3.0) \qquad (3.0) \qquad (4.2) \qquad (3.5)$	
Native 2,570 1,505 1,715 1,170	
American (0.7) (0.6) (0.7) (0.8)	
Other 11,785 6,585 10,215 4,875	
(3.1) (2.8) (4.0) (3.3)	
Quartile of Median Household Income by Zipcode (Percentile)	
<25 th 116,585 76,505 <0.001 76,210 47,690 <0.0	01
(30.5) (32.3) (29.0) (31.7)	
26 th – 50 th 99,445 61,950 70,715 40,985	
(26.0) (26.1) (27.0) (27.3)	
51 th - 75 th 90,070 54,665 63,025 34,420	
(23.6) (23.0) (24.0) (22.9)	
76 th - 100 th 76,250 44,125 52,075 27,325	
(19.9) (18.6) (19.9) (18.2)	
Insurance	
Medicare 223,675 155,185 <0.001 154,770 106,735 <0.0	01
(57.4) (64.4) (57.9) (69.9)	
Medicaid 55,630 31,890 28,365 14,545	
(14.3) (13.2) (10.6) (9.5)	
Private 82,505 43,480 60,715 24,240	
(21.2) (18.0) (22.7) (15.9)	
Self-Pay 13,670 5,905 12,610 4,630	

		1	1		1	
	(3.5)	(2.5)		(4.7)	(3.0)	
No Charge	695	365		810	305	
	(0.2)	(0.2)		(0.3)	(0.2)	
Other	13,805	4,040		10,105	2,275	
	(3.5)	(1.7)		(3.8)	(1.5)	
Hospital Type						
Government	47,950	28,495	0.013	26,165	14,035	< 0.001
	(12.3)	(11.8)		(9.8)	(9.2)	
Private, Non-	301,035	185,990		200,540	116,325	
Profit	(77.0)	(77.1)		(74.9)	(76.0)	
Private, For-	41,520	26,665		41,105	22,535	
Profit	(10.6)	(11.0)		(15.4)	(14.7)	
Hospital Teaching Sta		(11.0)		(10.1)	(1117)	
Rural	13,175	9,290	< 0.001	12,140	8,195	< 0.001
Kurar	(3.4)	(3.9)	<0.001	(4.5)	(5.4)	<0.001
Urban, Non-	52,265	34,915		46,230	26,635	
Teaching	(13.4)	(14.5)		(17.3)	(17.4)	
	` /	` ,		_ `	118,065	
Urban,	325,065	196,945		209,440	,	
Teaching	(83.2)	(81.7)		(78.2)	(77.2)	
Comorbidities & Pri	1		0.001	12 120	25.440	0.001
Obesity	68,960	49,945	< 0.001	42,130	27,410	< 0.001
	(17.7)	(20.7)		(15.7)	(17.9)	
Dyslipidemia	162,685	91,920	< 0.001	136,680	75,520	< 0.001
	(41.7)	(38.1)		(51.0)	(49.4)	
Diabetes Mellitus	149,720	88,565	< 0.001	112,160	67,555	< 0.001
	(38.3)	(36.7)		(41.9)	(44.2)	
Chronic	296,000	175,060	< 0.001	199,995	117,175	< 0.001
Hypertension	(75.8)	(72.6)		(74.7)	(76.6)	
Tobacco Use	48,555	22,225	< 0.001	46,430	21,345	< 0.001
	(12.4)	(9.2)		(17.3)	(14.0)	
Peripheral Vascular	21,535	11,165	< 0.001	19,510	11,575	0.137
Disease	(5.5)	(4.6)		(7.3)	(7.6)	
Chronic Heart	156,605	96,585	0.859	95,455	57,405	< 0.001
Failure	(40.1)	(40.0)		(35.6)	(37.6)	
Chronic Kidney	175,165	90,745	< 0.001	89,720	49,225	< 0.001
Disease	(44.9)	(37.6)		(33.5)	(32.2)	
Chronic Liver	101,045	56,175	< 0.001	61,715	31,420	< 0.001
Disease	(25.9)	(23.3)		(23.0)	(20.6)	
Valvular Heart	100,290	69,700	< 0.001	46,935	32,640	< 0.001
Disease	(25.7)	(28.9)		(17.5)	(21.4)	
Coronary Artery	195,860	86,305	< 0.001	202,640	103,145	< 0.001
Disease	(50.2)	(35.8)		(75.7)	(67.5)	
Stroke	13,035	8,715	0.007	11,500	7,470	< 0.001
SHORE	(3.3)	(3.6)	0.007	(4.3)	(4.9)	\0.001
Prior PCI	38,505	14,760	< 0.001	34,094	15,360	< 0.001
1 1101 1 C1	(9.9)	(6.1)	\U.UU1	(12.7)	(10.0)	\U.UU1
	(7.7)	(0.1)		(12.7)	(10.0)	

Prior CABG	39,770	12,175	< 0.001	24,925	9,785	< 0.001
	(10.2)	(5.0)		(9.3)	(6.4)	

Results presented as n (%). Comparisons made using pearson's χ^2 test. Comparisons made using pearson's χ^2 test for categorical variables and Mann-Whitney test for continuous variables. All analyses are survey weight adjusted. Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting.

Table 2. Frequency of procedural and clinical outcomes stratified by sex and CS type.

	N	Non-AMI-CS	3	AMI-CS			
	63	31,655 (60.02	2)	42	20,705 (39.98	3)	
	Male	Female	p-value	Male	Female	p-value	
	390,505	241,150	< 0.001	267,810	152,895	< 0.001	
	(61.8)	(38.2)		(63.7)	(36.3)		
Procedural Outcomes							
Revascularization	39,770	15,395	< 0.001	140,215	67,770	< 0.001	
	(10.2)	(6.4)		(52.4)	(44.3)		
PCI	9,385	4,555	< 0.001	104,185	53,160	< 0.001	
	(2.4)	(1.9)		(38.9)	(34.8)		
CABG	32,110	11,570	< 0.001	47,465	18,735	< 0.001	
	(8.2)	(4.8)		(17.7)	(12.3)		
MCS	49,290	21,795	< 0.001	96,320	41,710	< 0.001	
	(12.6)	(9.0)		(36.0)	(27.3)		
IABP	27,615	11,745	< 0.001	65,870	29,565	< 0.001	
	(7.1)	(4.9)		(24.6)	(19.3)		
pLVAD	18,655	6,875	< 0.001	32,750	13,050	< 0.001	
_	(4.8)	(2.5)		(12.2)	(8.5)		
ECMO	11,300	6,445	0.026	7,885	2,635	< 0.001	
	(2.9)	(2.7)		(2.9)	(1.7)		
RHC	82,485	40,015	< 0.001	51,600	25,800	< 0.001	
	(21.1)	(16.6)		(19.3)	(16.9)		
Advanced Heart Failure	17,100	5,590	< 0.001	1,580	510	< 0.001	
Therapy	(4.4)	(2.3)		(0.6)	(0.3)		
LVAD	10,630	3,100	< 0.001	1,300	380	< 0.001	
	(2.7)	(1.3)		(0.5)	(0.3)		
Heart Transplant	6,595	2,530	< 0.001	310	130	0.151	
	(1.7)	(1.0)		(0.1)	(0.1)		
Clinical Outcomes							
In-hospital Mortality	118,205	85,360	< 0.001	90,940	58,355	< 0.001	
	(30.3)	(35.4)		(34.0)	(38.2)		
Invasive Mechanical	106,950	74,690	< 0.001	89,655	52,860	0.001	
Ventilation	(27.4)	(31.0)		(33.5)	(34.6)		
Major Bleeding	81,895	48,495	< 0.001	53,865	29,420	0.003	
	(21.0)	(20.1)		(20.1)	(19.2)		
Acute Kidney Injury	265,625	149,005	< 0.001	163,645	85,090	< 0.001	
	(68.0)	(61.8)		(61.1)	(55.7)		
Acute Kidney Injury	31,800	17,715	< 0.001	18,270	8.755	< 0.001	

Requiring Dialysis	(8.1)	(7.4)		(6.8)	(5.7)	
Stroke	985	1,025	< 0.001	645	605	< 0.001
	(0.3)	(0.4)		(0.2)	(0.4)	
Total Hospitalization Cost	268,220.4	233,424.5	< 0.001	254,776.1	216,624.1	< 0.001
in USD (mean, standard	(4,607.4)	(3,528.7)		(2,762.1)	(2,376.2)	
error)						
Length of Stay in days	12.65	11.82	< 0.001	9.99	9.32	< 0.001
(mean, standard error)	(0.10)	(0.10)		(0.06)	(0.07)	

Results presented as (%), unless otherwise noted. Comparisons made using pearson's χ^2 test for categorical variables. All analyses are survey weight adjusted.

Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MCS, mechanical support device; IABP, intra-aortic balloon pump; pLVAD, percutaneous left ventricular support device; ECMO, extracorporeal membrane oxygenation; RHC, right heart catheterization; LVAD, left ventricular assist device.

Table 3. Odds ratios of clinical outcomes in women versus men with AMI-CS based on first intervention type received.

Outcomes in Women	Unadjusted Odds	p-value	Model 1 (Only	p-	Model 2 (All	p-value
compared to Men	Ratio		Demographics)	value	Baseline	
			Odds Ratio		Characteristics)	
					Odds Ratio	
Revascularization						
In-hospital Mortality	1.23 (1.18-1.29)	< 0.001	1.13 (1.08-1.19)	< 0.001	1.15 (1.09-1.22)	< 0.001
IMV	1.06 (1.01-1.10)	0.011	1.06 (1.01-1.10)	0.013	1.07 (1.02-1.12)	0.003
Major Bleeding	1.02 (0.97-1.07)	0.322	1.02 (0.98-1.08)	0.245	0.98 (0.94-1.04)	0.689
AKI	0.79 (0.76-0.83)	< 0.001	0.73 (0.70-0.76)	< 0.001	0.71 (0.67-0.74)	< 0.001
AKI Requiring Dialysis	0.89 (0.81-0.98)	0.021	0.87 (0.79-0.97)	0.013	0.86 (0.77-0.96)	0.007
Stroke	1.78 (1.25-3.52)	0.001	1.67 (1.16-2.40)	0.006	1.62 (1.12-2.35)	0.010
MCS						
In-hospital Mortality	1.19 (1.13-1.26)	< 0.001	1.12 (1.06-1.19)	< 0.001	1.15 (1.08-1.22)	< 0.001
IMV	1.11 (1.05-1.17)	< 0.001	1.10 (1.04-1.17)	0.001	1.12 (1.06-1.19)	< 0.001
Major Bleeding	1.10 (1.04-1.17)	0.001	1.11 (1.04-1.18)	0.001	1.08 (1.01-1.15)	0.015
AKI	0.78 (0.74-0.82)	< 0.001	0.74 (0.70-0.78)	< 0.001	0.72 (0.68-0.76)	< 0.001
AKI Requiring Dialysis	0.85 (0.77-0.94)	0.003	0.84 (0.76-0.94)	0.002	0.83 (0.74-0.93)	0.002
Stroke	1.52 (0.92-2.50)	0.104	1.46 (0.87-2.45)	0.153	1.33 (0.77-2.29)	0.309
RHC						
In-hospital Mortality	1.12 (1.04-1.20)	0.001	1.06 (0.99-1.15)	0.085	1.10 (1.02-1.19)	0.008
IMV	1.09 (1.02-1.18)	0.008	1.11 (1.04-1.20)	0.003	1.12 (1.04-1.21)	0.002
Major Bleeding	1.03 (0.96-1.11)	0.357	1.05 (0.98-1.14)	0.158	1.03 (0.95-1.12)	0.378
AKI	0.71 (0.66-0.76)	< 0.001	0.68 (0.63-0.73)	< 0.001	0.69 (0.64-0.75)	< 0.001
AKI Requiring Dialysis	0.76 (0.67-0.86)	< 0.001	0.73 (0.64-0.83)	< 0.001	0.76 (0.66-0.87)	< 0.001
Stroke	1.12 (0.63-1.99)	0.687	1.06 (0.59-1.90)	0.837	0.96 (0.52-1.77)	0.901
Advanced Heart Failure	Therapy					
In-hospital Mortality	1.13 (0.58-2.20)	0.705	1.12 (0.48-2.59)	0.790	1.37 (0.54-3.50)	0.503
IMV	1.17 (0.63-2.15)	0.618	1.11 (0.55-2.25)	0.751	1.16 (0.58-2.34)	0.667
Major Bleeding	1.26 (0.77-2.08)	0.352	1.64 (0.91-2.96)	0.096	1.59 (0.87-2.89)	0.126

AKI	0.77 (0.44-1.35)	0.363	0.85 (0.48-1.51)	0.579	0.81 (0.41-1.58)	0.525
AKI Requiring Dialysis	1.21 (0.57-2.58)	0.616	1.53 (0.61-3.87)	0.360	1.76 (0.58-5.33)	0.317
Stroke	1.55 (0.14-17.6)	0.721	9.66 (0.52-179)	0.124	N/A	N/A

All analyses involve multivariate logistic regression and are survey weight adjusted. Model 1 includes adjustment with year of NIS data, age group, race, household income quartile, insurance status, hospital type and teaching status. Model 2 includes adjustment with all model 1 covariates as well as past medical history of diabetes mellitus, hypertension, dyslipidemia, tobacco use, obesity, chronic kidney disease, liver disease, peripheral vascular disease, coronary artery disease, chronic heart failure, valvular heart disease, stroke, prior PCI, and prior CABG. Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; MCS, mechanical support device; RHC, right heart catheterization; IMV, invasive mechanical ventilation; AKI, acute kidney injury.

Table 4. Odds ratios of clinical outcomes in women versus men with Non-AMI-CS based on first intervention type received.

Outcomes in Women	Unadjusted Odds	p-value	Model 1 (Only	p-value	Model 2 (All	p-value
compared to Men	Ratio		Demographics)		Baseline	
			Odds Ratio		Characteristics)	
					Odds Ratio	
Revascularization						
In-hospital Mortality	1.43 (1.28-1.59)	< 0.001	1.37 (1.22-1.54)	< 0.001	1.38 (1.23-1.56)	< 0.001
IMV	1.11 (1.00-1.23)	0.033	1.10 (0.99-1.23)	0.060	1.11 (1.00-1.24)	0.050
Major Bleeding	1.11 (1.02-1.21)	0.011	1.16 (1.06-1.27)	0.001	1.09 (0.99-1.19)	0.068
AKI	0.86 (0.79-0.94)	0.001	0.86 (0.78-0.94)	0.001	0.82 (0.74-0.90)	< 0.001
AKI Requiring Dialysis	1.01 (0.85-1.21)	0.856	0.99 (0.82-1.19)	0.924	0.95 (0.78-1.16)	0.638
Stroke	1.29 (0.67-2.48)	0.439	1.42 (0.71-2.86)	0.318	1.32 (0.66-2.65)	0.423
MCS						
In-hospital Mortality	1.30 (1.20-1.40)	< 0.001	1.30 (1.20-1.42)	< 0.001	1.31 (1.21-1.43)	< 0.001
IMV	1.27 (1.17-1.37)	< 0.001	1.27 (1.17-1.39)	< 0.001	1.28 (1.18-1.40)	< 0.001
Major Bleeding	1.12 (1.05-1.20)	0.001	1.14 (1.06-1.23)	< 0.001	1.10 (1.02-1.18)	0.012
AKI	0.68 (0.63-0.73)	< 0.001	0.67 (0.62-0.73)	< 0.001	0.66 (0.60-0.73)	< 0.001
AKI Requiring Dialysis	0.91 (0.82-1.02)	0.114	0.91 (0.81-1.02)	0.126	0.94 (0.82-1.06)	0.324
Stroke	1.64 (0.96-2.83)	0.070	1.69 (0.96-2.98)	0.068	1.64 (0.93-2.89)	0.089
RHC						
In-hospital Mortality	1.30 (1.21-1.39)	< 0.001	1.31 (1.22-1.41)	< 0.001	1.32 (1.22-1.43)	< 0.001
IMV	1.30 (1.21-1.39)	< 0.001	1.31 (1.22-1.41)	< 0.001	1.27 (1.17-1.36)	< 0.001
Major Bleeding	1.01 (0.95-1.08)	0.609	1.02 (0.96-1.09)	0.427	0.98 (0.91-1.04)	0.507
AKI	0.69 (0.65-0.73)	< 0.001	0.68 (0.64-0.72)	< 0.001	0.73 (0.68-0.77)	< 0.001
AKI Requiring Dialysis	0.95 (0.86-1.04)	0.285	0.95 (0.85-1.04)	0.273	1.00 (0.90-1.11)	0.970
Stroke	1.45 (0.89-2.37)	0.127	1.54 (0.93-2.56)	0.090	1.55 (0.91-2.63)	0.104
Advanced Heart Failure	Therapy					
In-hospital Mortality	1.05 (0.81-1.36)	0.671	1.13 (0.86-1.50)	0.361	1.20 (0.88-1.63)	0.242
IMV	1.00 (0.81-1.23)	0.952	0.99 (0.79-1.24)	0.969	1.05 (0.84-1.31)	0.635
Major Bleeding	1.03 (0.88-1.20)	0.665	0.99 (0.84-1.16)	0.906	1.02 (0.87-1.20)	0.768
AKI	0.62 (0.52-0.72)	< 0.001	0.61 (0.52-0.71)	< 0.001	0.68 (0.57-0.81)	< 0.001
AKI Requiring Dialysis	0.79 (0.59-1.05)	0.115	0.76 (0.57-1.03)	0.081	0.79 (0.57-1.09)	0.157
Stroke	1.45 (0.65-3.20)	0.354	1.39 (0.60-3.22)	0.432	1.44 (0.62-3.35)	0.393

All analyses involve multivariate logistic regression and are survey weight adjusted. Model 1 includes adjustment with year of NIS data, age group, race, household income quartile, insurance status, hospital type and teaching

status. Model 2 includes adjustment with all model 1 covariates as well as past medical history of diabetes mellitus, hypertension, dyslipidemia, tobacco use, obesity, chronic kidney disease, liver disease, peripheral vascular disease, coronary artery disease, chronic heart failure, valvular heart disease, stroke, prior PCI, and prior CABG. Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; MCS, mechanical support device; RHC, right heart catheterization; IMV, invasive mechanical ventilation; AKI, acute kidney injury.

Table 5. Odds ratios of in-hospital mortality in women receiving early (within 24 hours) versus

late or no intervention by CS type.

In-hospital Mortality	Unadjusted	p-value	Model 1 (Only	p-value	Model 2 (All	p-value
in Women Receiving	Odds Ratio		Demographics)		Baseline	
Early Intervention			Odds Ratio		Characteristics) Odds	
compared to Women					Ratio	
Not Receiving Early						
Intervention						
AMI-CS						
Revascularization	0.65 (0.61-0.69)	< 0.001	0.66 (0.62-0.70)	< 0.001	0.77 (0.72-0.82)	< 0.001
PCI	0.66 (0.63-0.71)	< 0.001	0.68 (0.64-0.72)	< 0.001	0.79 (0.74-0.85)	< 0.001
CABG	0.63 (0.55-0.73)	< 0.001	0.63 (0.55-0.74)	< 0.001	0.69 (0.59-0.82)	< 0.001
MCS	0.87 (0.82-0.93)	< 0.001	0.94 (0.88-1.00)	0.068	1.06 (0.99-1.14)	0.073
IABP	0.69 (0.64-0.75)	< 0.001	0.72 (0.67-0.78)	< 0.001	0.83 (0.77-0.91)	< 0.001
pLVAD	1.50 (1.35-1.68)	< 0.001	1.67 (1.49-1.88)	< 0.001	1.78 (1.58-2.01)	< 0.001
ECMO	1.71 (1.32-2.2)	< 0.001	2.38 (1.83-3.10)	< 0.001	2.15 (1.62-2.85)	< 0.001
RHC	0.87 (0.79-0.96)	0.005	0.90 (0.819-0.99)	0.048	0.979 (0.88-1.08)	0.688
Non-AMI-CS						
Revascularization	0.42 (0.37-0.49)	< 0.001	0.42 (0.36-0.49)	< 0.001	0.57 (0.49-0.67)	< 0.001
PCI	0.76 (0.60-0.95)	0.017	0.70 (0.55-0.88)	0.003	0.87 (0.68-1.12)	0.296
CABG	0.32 (0.27-0.39)	< 0.001	0.33 (0.28-0.40)	< 0.001	0.46 (0.38-0.56)	< 0.001
MCS	0.92 (0.82-1.01)	0.109	0.97 (0.87-1.09)	0.663	1.05 (0.94-1.18)	0.360
IABP	0.64 (0.54-0.74)	< 0.001	0.65 (0.55-0.77)	< 0.001	0.78 (0.67-0.93)	0.005
pLVAD	1.41 (1.14-1.74)	0.001	1.48 (1.19-1.84)	< 0.001	1.56 (1.24-1.96)	< 0.001
ECMO	1.31 (1.10-1.57)	0.002	1.52 (1.26-1.82)	< 0.001	1.40 (1.15-1.69)	0.001
RHC	0.42 (0.37-0.46)	< 0.001	0.45 (0.39-0.50)	< 0.001	0.50 (0.44-0.57)	< 0.001

All analyses involve multivariate logistic regression and are survey weight adjusted. Model 1 includes adjustment with year of NIS data, age group, race, household income quartile, insurance status, hospital type and teaching status. Model 2 includes adjustment with all model 1 covariates as well as past medical history of diabetes mellitus, hypertension, dyslipidemia, tobacco use, obesity, chronic kidney disease, liver disease, peripheral vascular disease, coronary artery disease, chronic heart failure, valvular heart disease, stroke, prior PCI, and prior CABG. Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MCS, mechanical support device; IABP, intra-aortic balloon pump; pLVAD, percutaneous left ventricular support device; ECMO, extracorporeal membrane oxygenation; RHC, right heart catheterization; LVAD, left ventricular assist device.

Figure 1. Frequency of early intervention within 24 hours stratified by sex and CS type. Unadjusted results. Figure 1A and 1B shows results for non-AMI-CS and AMI-CS, respectively. Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MCS, mechanical support device; IABP, intra-aortic balloon pump; pLVAD, percutaneous left ventricular support device; ECMO, extracorporeal membrane oxygenation; RHC, right heart catheterization; LVAD, left ventricular assist device.






Figure 2. Adjusted odds ratios of receiving early intervention within 24 hours of admission stratified by CS type.

All analyses involve multivariate logistic regression and are survey weight adjusted. Odds ratios reported are adjusted for year of NIS data, age group, race, household income quartile, insurance status, hospital type and teaching status as well as past medical history of diabetes mellitus, hypertension, dyslipidemia, tobacco use, obesity, chronic kidney disease, liver disease, peripheral vascular disease, coronary artery disease, chronic heart failure, valvular heart disease, stroke, prior PCI, and prior CABG.

Note: advanced heart failure therapies data not reported due to low counts preventing proper construction of logistic regression.

Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MCS, mechanical support device; IABP, intra-aortic balloon pump; pLVAD, percutaneous left ventricular support device; ECMO, extracorporeal membrane oxygenation; RHC, right heart catheterization.




Figure 3. Adjusted odds ratios of in-hospital mortality following early intervention within 24 hours of admission stratified by CS type.

All analyses involve multivariate logistic regression and are survey weight adjusted. Each regression is performed on a dataset filtered to only include CS patients who received a particular intervention within 24 hours. Odds ratios reported are adjusted for year of NIS data, age group, race, household income quartile, insurance status, hospital type and teaching status as well as past medical history of diabetes mellitus, hypertension, dyslipidemia, tobacco use, obesity, chronic kidney disease, liver disease, peripheral vascular disease, coronary artery disease, chronic heart failure, valvular heart disease, stroke, prior PCI, and prior CABG.

Note: advanced heart failure therapies data not reported due to low counts preventing proper construction of logistic regression.

Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MCS, mechanical support device; IABP, intra-aortic balloon pump; pLVAD, percutaneous left ventricular support device; ECMO, extracorporeal membrane oxygenation; RHC, right heart catheterization.

